Mankind Pharma (NSE:MANKIND) Earnings Power Value (EPV): ₹-1,682.76 (As of Jun26)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANKIND Mankind Pharma Ltd NSE:MANKIND
91 GF Score
Price ₹2,425.20
GF Value ₹2,948.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Mankind Pharma Earnings Power Value (EPV)?

Mankind Pharma NSE:MANKIND +0.87% 91 Earnings Power Value (EPV) is ₹-1,682.76 as of Jun26. GuruFocus rates NSE:MANKIND with a GF Score™ of 91/100 and a GF Value™ of ₹2,948.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

As of Jun26, Mankind Pharma's earnings power value is ₹-1,682.76. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Mankind Pharma  (NSE:MANKIND) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Mankind Pharma Earnings Power Value (EPV) Related Terms


Mankind Pharma Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Mankind Pharma's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mankind Pharma Earnings Power Value (EPV) Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Earnings Power Value (EPV)
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mankind Pharma Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1,682.17

NSE:MANKIND vs ZTS: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Earnings Power Value (EPV) falls into.


NSE:MANKIND
91GF Score
Mankind Pharma Ltd NSE:MANKIND
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mankind Pharma Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Mankind Pharma's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 102,500
DDA 4,970
Operating Margin % 17.60
SGA * 25% 100
Tax Rate % 18.17
Maintenance Capex 77,912
Cash and Cash Equivalents 0
Short-Term Debt 0
Long-Term Debt 0
Shares Outstanding (Diluted) 413

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = 17.60%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = ₹102,500 Mil, Average Operating Margin = 17.60%, Average Adjusted SGA = 100,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 102,500 * 17.60% +100 = ₹18142.84621724 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 18.17%, and "Normalized" EBIT = ₹18142.84621724 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 18142.84621724 * ( 1 - 18.17% ) = ₹14845.837488412 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 4,970 * 0.5 * 18.17% = ₹451.5498256875 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 14845.837488412 + 451.5498256875 = ₹15297.3873141 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Mankind Pharma's Average Maintenance CAPEX = ₹77,912 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Mankind Pharma's current cash and cash equivalent = ₹0 Mil.
Mankind Pharma's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 0 + 0 = ₹0 Mil.
Mankind Pharma's current Shares Outstanding (Diluted Average) = 413 Mil.

Mankind Pharma's Earnings Power Value (EPV) for Jun26 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 15297.3873141 - 77,912)/ 9%+0-0 )/413
=-1,682.76

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -1682.7638547481-2425.20 )/-1682.7638547481
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of ₹-1,682.76 mean?
Mankind Pharma (NSE:MANKIND) has a Earnings Power Value (EPV) of ₹-1,682.76 as of Jun26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Mankind Pharma and its competitors.
Is Mankind Pharma's Earnings Power Value (EPV) too high?
Mankind Pharma's current Earnings Power Value (EPV) is ₹-1,682.76. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Earnings Power Value (EPV) compare to ZTS?
Mankind Pharma's Earnings Power Value (EPV) of ₹-1,682.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Mankind Pharma and its competitors. Mankind Pharma's current Earnings Power Value (EPV) is ₹-1,682.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (NSE:MANKIND) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,948.17, compared to a current price of ₹2,425.20 — trading 17.7% below its estimated fair value. The current Earnings Power Value (EPV) is ₹-1,682.76. Mankind Pharma's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Mankind Pharma (NSE:MANKIND), the current Earnings Power Value (EPV) is ₹-1,682.76 as of Jun26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mankind Pharma (NSE:MANKIND) Overvalued in 2026?

Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued. The current stock price of ₹2,425.20 is trading 17.7% below its estimated GF Value™ of ₹2,948.17. GuruFocus considers Mankind Pharma to be Modestly Undervalued.

Key valuation signals for NSE:MANKIND:

  • Earnings Power Value (EPV): ₹-1,682.76
  • GF Value™: ₹2,948.17 vs. price of ₹2,425.20 (17.7% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANKIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mankind Pharma Business Description

Other Exchanges 543904:India
Address 262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score

Get the complete analysis for NSE:MANKIND

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,425.20
Price
₹2,948.17
GF Value